Gerda Redl

Title: Gerda Redl: Innovator in Cytotoxic Antibodies

Introduction

Gerda Redl is a prominent inventor based in Gross-Enzersdorf, Austria. She has made significant contributions to the field of biotechnology, particularly in the development of cytotoxic antibodies. With a total of 8 patents to her name, her work has the potential to impact therapeutic applications significantly.

Latest Patents

One of her latest patents is focused on a cytotoxic immunoglobulin. This invention relates to a modular antibody with a molecular weight of up to 60 kD, specifically designed to bind to a cell surface target with a binding affinity of Kd < 10M. The patent also details a method for producing such antibodies and their therapeutic uses. Another notable patent involves the display of binding agents. This application describes a method for preparing a genetic package that displays oligomers of modular antibody domains that bind to a target and a scaffold ligand. It also includes vectors and libraries of genetic packages produced through this method, along with techniques for selecting suitable linker sequences for use in oligomer display.

Career Highlights

Throughout her career, Gerda has worked with notable companies in the biotechnology sector, including F-star Biotechnologische Forschungs- und Entwicklungsges.m.b.h. Her innovative work has positioned her as a key figure in her field.

Collaborations

Gerda has collaborated with esteemed colleagues such as Gottfried Himmler and Geert Mudde. These partnerships have further enhanced her research and development efforts.

Conclusion

Gerda Redl's contributions to the field of biotechnology, particularly in the area of cytotoxic antibodies, showcase her innovative spirit and dedication to advancing therapeutic solutions. Her work continues to inspire future developments in the industry.